CAVE CREEK, AZ--(NewMediaWire - Apr 20, 2016) - Endexx
Corporation (OTC PINK: EDXC), a provider of innovative hemp derived
phyto-nutrients and nutritional products, today announced the
launch of a doctor supervised, adaptive clinical study to test the
efficacy of its proprietary CBD capsule in response to patients
suffering from neuropathic pain.
Dr. Martin Pressman, DPM in New Haven, Connecticut, Dr. Daniel
Brandwein, DPM in Weston, Florida, Dr. Michael Horwitz, DPM and Dr.
Daniel Kiddy, DPM, both in St Louis, Missouri will enroll twenty
patients into four groups, for a one month study using CBD enriched
capsules to evaluate neuropathic pain reduction.
The proprietary formulations are pharmacist formulated and
manufactured capsules which include a dual pack as a day and night
formula with cannabidiol as its primary active ingredient. Each
patient will be taking two capsules a day with results to be
monitored. At the end of the study, findings will be subjected to
an independent peer review board.
This study is an extension of the work conducted by Dr. Kiddy
with his patients and a follow up of Dr. Brandwein's research that
demonstrated an average pain reduction after 2 weeks of usage from
7 to 8 down to 3 to 4 on a pain scale of 1 to 10, using 4 to 5
drops of CBD-rich hemp oil twice a day.
Dr. Brandwein stated, "I am very excited about the upcoming new
trial where we can follow the information even closer. I also
believe that in a capsule form, patients will be more compliant and
have better results. In some cases, my patients have decreased and
discontinued their usage of Neurontin and Gabapentin."
Todd Davis, CEO of Endexx provided an update to shareholders on
its CBD initiative, and commented, "Endexx has defined two key
market pathways for its CBD initiative: the consumer market for
wellness and nutrition and the therapeutic and nutraceutical
markets. Through the consumer market we are targeting the
'Platinum' age 40+ demographic seeking prolonged wellness, improved
quality of life and the extension of an active lifestyle. Our
phyto-cannabinoids-rich (PCR) products with Cannabidiol from
Industrial Hemp have proven to significantly enhance overall
wellness and improve physical and mental condition. On the
therapeutic side, we have been formulating and testing CBD-infused
products with certified compound pharmacists and physicians in a
medical environment. Through this collaborative effort we have been
able produce high-quality, safe and effective products and delivery
formats. Physicians want to provide methods of treatment that
support patient compliance and provide a clear beneficial solution
for their patients."
About Endexx
Endexx provides innovative medical marijuana management and
technology solutions. Endexx, with its collaborative partners and
consultants, develops and distributes consumable product lines
derived from industrial hemp that is GMO and pesticides free and
naturally rich in phytocannabinoids. The company has two technology
products and services that launched in 2014 -- the M3hub and the
Autospense™. Both products provide essential solutions to promote
regulatory compliance and full accountability through "seed to
sale" inventory management and tracking. Based on principles
developed by the pharmacological industry, the m3hub platform is
the first standardized software solution for tracking
pharmaceutical grade marijuana that maintains compliance with
federal, state and local regulations. It is intended to provide a
smooth transition to an eventual federal mandates. The Autospense™
is a high-tech marijuana inventory control and dispensing device
that provides up-to-the-minute accounting details and ensures both
product and patient security. By automating the dispensing process,
Autospense™ increases productivity and reduces costs for marijuana
retailer, while enhancing their service quality by reducing
transaction time for customers. Websites include: www.cbdunlimited.com, www.cbdhealthsolutions.com, www.endexx.com, www.m3hub.com.
Safe Harbor Notice
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, such as statements relating to financial results and plans
for future development activities, and are thus prospective.
Forward-looking statements include all statements that are not
statements of historical fact regarding intent, belief or current
expectations of the Company, its directors or its officers.
Investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, many of which are beyond the Company's ability to
control. Actual results may differ materially from those projected
in the forward-looking statements. Among the factors that could
cause actual results to differ materially from those indicated in
the forward-looking statements are risks and uncertainties
associated with the Company's business and finances in general,
including the ability to continue and manage its growth,
competition, global economic conditions and other factors discussed
in detail in the Company's periodic filings with the Security and
Exchange Commission. The Company undertakes no obligation to update
any forward-looking statements.
